Test with Confidence. Test with ZEUS.
Learn about the importance of early Lyme disease detection and the how a paradigm shift in testing can make a real difference to patients.
Daniel Zweitzig, PhD., Vice President of Research & Development at ZEUS Scientific reviews the history of Lyme disease and chronicles ZEUS’s 33-year journey of pioneering new Lyme disease diagnostics from the first FDA-cleared Lyme Serology product to the first FDA-cleared Borrelia Modified Two-Tiered Testing (MTTT™) algorithm. He outlines several publications and activities that pointed ZEUS in the direction to validate a replacement of the Standard Two-Tiered Testing (STTT) algorithm. This STTT algorithm has documented shortcomings and has been the recommended Lyme disease serology algorithm for more than 25 years. Until now.
Sign up for on-demand access and find out how we can change the game together by detecting more stage 1 and stage 2 Lyme disease.
Visit zeuslyme.com to learn more.
The all-ELISA algorithm is the simple, sensitive, and specific alternative that is changing the game in Lyme disease testing.
If you are still running Lyme disease immunoblots in your laboratory, take a look at the clinical data to see how ZEUS Borrelia MTTT™ improves detection in early Lyme disease.